24 June 2026
24 June 2026
Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.
The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.
The outcomes are intended to form the clinical basis for CereVasc’s PMA submission to the FDA.
ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
